Lung oedema induced by Tityus serrulatus scorpion venom in the rat.
The effects of drugs were investigated on the induction of acute lung oedema by scorpion Tityus serrulatus venom in male Wistar rats (200-230 g) anaesthetized with sodium pentobarbital (40 mg/kg, i.p.). Intravenous (i.v.) injection of scorpion venom (0.5 mg/kg) into 12 rats induced arterial hypertension and severe lung oedema, whereas i.v. injection of scorpion venom into 16 rats previously injected with commercial heparin induced arterial hypertension, but only a slight lung oedema. It is suggested that the inhibitory effect of commercial heparin on the genesis of lung oedema may be due to a decrease in vascular permeability in the lungs. Previous i.v. injection of aprotinin did not prevent the arterial hypertension and the lung oedema induced by scorpion venom. Previous injections of platelet-activating factor antagonists (BN-52021 and WEB-2170) or of an inhibitor of lipo- and cyclooxygenase (Nordihydroguaiaretic acid) did not prevent the arterial hypertension induced by scorpion venom, but decreased the magnitude of the lung oedema elicited by the venom. Previous injections of inhibitors of 5-lipoxygenase (MK-886) or cyclooxygenase (aspirin or indomethacin) significantly decreased the magnitude of the lung oedema induced by scorpion venom. It is concluded that the release of vascular permeability factors, such as platelet-activating factors, leukotrienes, and prostaglandins may play a role in the induction of acute lung oedema by scorpion venom in rats.
De Matos
I M
IM
Departamento de Farmacologia, ICB-UFMG, Belo Horizonte, M.G., Brazil.
Rocha
O A
OA
Leite
R
R
Freire-Maia
L
L
D000818:Animals; D007611:Aprotinin / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D002199:Capillary Permeability / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004224:Diterpenes; D004347:Drug Interactions; D005343:Fibrinolytic Agents / Q000494:pharmacology; D046934:Ginkgolides; D006490:Hemostatics / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006973:Hypertension / Q000139:chemically induced*; D007275:Injections, Intravenous; D007783:Lactones / Q000494:pharmacology; D015289:Leukotrienes / Q000378:metabolism; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D012604:Scorpion Venoms / Q000008:administration & dosage; D014230:Triazoles / Q000494:pharmacology
D001381:Azepines; D016861:Cyclooxygenase Inhibitors; D004224:Diterpenes; D005343:Fibrinolytic Agents; D046934:Ginkgolides; D006490:Hemostatics; D007783:Lactones; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D011453:Prostaglandins; D012604:Scorpion Venoms; D014230:Triazoles; D009637:Masoprocol; D006493:Heparin; D007611:Aprotinin; C063964:bepafant; C045856:ginkgolide B